Bohlen et al., 1993, "Cytolysis Of Leukemic B-Cells By T-Cells Activated Two Bispecifc Antibodies," Cancer Research 53: 4310-4314. |
Bohlen et al., 1993, "Lysis Of Malignant B Cells From Patients With B-Chronic Lymphocytic Leukemia By Autologous T Cells Activated With CD3 .times. CD19 Bispecific Antibodies In Combination With Bivalent CD28 Antibodies," Blood 82:1803-1812. |
Ertel et al., 1993, "Viral Hemagglutinin Augments Peptide-Specific Cytotxic T Cell Responses," European Journal of Immunology 23:2592-2596. |
Fanger et al., 1992, "Bispecific Antibodies," Critical Reviews in Immunology 12:101-124. |
Nishimura et al., 1992, "Human c-erbB-2 Proto-Oncogene Product As A Target For Bispecific-Antibody-Directed Adoptive Tumor Immunotherapy," International Journal of Cancer 50:800-804. |
Schirrmacher, 1993, "Active Specific Immunotherapy--A New Modality Of Cancer Treatment Involving The Patient's Own Immune System," Onkologie 16:290-296. |
Azuma et al., 1993, "B70 antigen is a second ligand for CTLA-4 and CD28," Nature 366: 76-79. |
Dubel et al., 1993, "A family of vectors for surface display and production of antibodies," Gene 128:97-101. |
Freeman et al., 1993, "Cloning of B7-2: A CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation," Science 262:909-911. |
Iorio et al., 1986, "Genetic Variation within a Neutralizing Domain on the Haemagglutinin-Neuraminidase Glycoprotein of Newcastle Disease Virus," J. gen. Virol. 67:1393-1403. |
Kurucs et al., 1993, "A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor," Proc. Natl. Acad. Sci. USA 90:3830-3834. |